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Abstract 
 
The presence of a leaving group at C-4 of monobactams is usually considered to be a requirement for 
mechanism-based inhibition of human leukocyte elastase by these acylating agents. We report that 
second-order rate constants for the alkaline hydrolysis and elastase inactivation by N-carbamoyl 
monobactams are independent of the pKa of the leaving group at C-4. Indeed, the effect exerted by 
these substituents is purely inductive: electron-withdrawing substituents at C-4 of N-carbamoyl-3,3-
diethylmonobactams increase the rate of alkaline hydrolysis and elastase inactivation, with Hammett 
ρI values of 3.4 and 2.5, respectively, which indicate the development of a negative charge in the 
transition-states. The difference in magnitude between these ρI values is consistent with an earlier 
transition-state for the enzymatic reaction when compared with that for the chemical process. These 
results suggest that rate limiting step in elastase inactivation is the formation of the tetrahedral 
intermediate, and that β-lactam ring-opening is not concerted with the departure of a leaving group 
from C-4.  Monobactam sulfones emerged as potent elastase inhibitors even when the ethyl groups at 
C-3, required for interaction with the primary recognition site, are absent. For one such compound, a 
1:1 enzyme-inhibitor complex involving porcine pancreatic elastase has been examined by X-ray 
crystallography and shown to result from serine acylation and sulfinate departure from the β-lactam 
C-4.  
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 β-Lactams are potent inhibitors of a wide range of enzymes that contain a catalytic serine 
residue, including the hepatitis C virus serine protease, penicillin binding proteins (PBPs), β-
lactamases and human leukocyte elastase (HLE). 1-7 The efficiency of β-lactams as enzyme inhibitors 
depends on the molecular recognition by the protein as well as on the intrinsic chemical reactivity of 
the β-lactam, both of which affect the rate at which these inhibitors acylate the serine residue. 8  
Among the most extensively studied enzymatic reactions of β-lactams is the inhibition of 
class A β-lactamases by penam sulfone inhibitors such as sulbactam, 1 (Scheme 1), tazobactam and 
their analogues. 9-15 Reaction of penam sulfones with the catalytic Ser70 involves β-lactam ring-
opening and leads to the departure of a sulfinate leaving group from C-5 and formation of an imine 
(Scheme 1). 1,14 The imine then undergoes a cascade of reactions including nucleophilic attack by 
Ser130 hydroxyl group to form a stable acrylate ester capable of preventing hydrolysis of the acyl-
enzyme, and thus leading to irreversible inhibition. 11 The oxidation state of the sulfur atom in the 
penam plays a role in potency: while sulbactam is a potent β-lactamase inhibitor, its penicillanate 
counterpart is only a substrate of β-lactamase, while the corresponding sulfoxides are both substrate 
and weak inactivators. 10 Worth noting, β-lactamase inhibition by clavulanic acid, 2, requires 
intramolecular hydrogen bonding from the C-9 hydroxyl group to assist the departure of an oxonium 
oxygen from C-5, i.e. 3. 16 These results suggest that departure of a good leaving group from the C-5 
carbon atom of penams and clavams is required to achieve irreversible inhibition of enzymes 
containing a catalytic serine residue. 10,17  
Cephalosporins are time-dependent inhibitors of HLE inhibitors, and, similarly to penams, 
the oxidation state of the sulfur atom also plays a role in potency, with sulfones (4, n = 2) showing 
considerably greater activity than the corresponding sulfides (4, n = 0) or β-sulfoxides (4, n = 1), 
while α-sulfoxides are inactive. 18-21 However, the identity of the species giving rise to inhibition 
remains to be defined. X-Ray crystallography indicates that inactivation of HLE by cephalosporin 
sulfones containing a good leaving group at C’-3 (e.g. 4, X = AcO) preferably involves reaction with 
His57 at this position rather than sulfinic acid departure from C-6 and thiazine ring-opening. 22 
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Monobactams containing potential leaving groups at C-4 were also developed as mechanism-
based inhibitors of HLE, 23-25 although the requirement of leaving-group departure to achieve 
irreversible inactivation is still controversial. Crystallography 26 and mass spectrometry 27 studies 
indicate that the reaction of monobactams containing a C-4 aryloxy substituent with HLE involves 
the departure of a phenol, possibly concerted with C-N bond fission and β-lactam ring-opening. 28 
However, the observation that the second-order rate-constants for HLE inactivation by monobactams 
with no leaving group at C-4 do not differ significantly from those of monobactams containing a 
phenol 28 suggests that leaving group ability is not essential to inactivate the enzyme. Understanding 
how β-lactam substituents affects molecular recognition by the enzyme and “chemical reactivity” is 
most useful in designing more potent enzyme inhibitors. We report here a study on the chemistry of 
elastase inactivation by model monobactams, 5, (Scheme 2, Table 1) with the objective of 
elucidating how C-4 substituents contribute to the chemical reactivity towards the catalytic serine. 
The results herein presented show that the effect exerted by these substituents is largely inductive 
and that sulfones at C-4 are particularly efficient in activating the β-lactam scaffold towards elastase.      
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RESULTS AND DISCUSSION 
 
1. Chemistry 
The synthesis of compounds 5 used the appropriate 4-acetoxyazetidin-2-one 6 24 as starting material 
to give direct access to the differently C-4 substituted azetidin-2-one key intermediates 7-10 (Scheme 
2). Reaction of 4-acetoxyazetidin-4-ones 6 with phenol 24 or thiols 29 and sodium hydroxide in 
acetone at room temperature gave the corresponding C-4 substituted β-lactams 7 and 8, respectively. 
Alternatively, 8a was synthesised by refluxing 6a with thiophenol in benzene. 30 Treatment of 
thioethers 8 with 3-chloroperbenzoic acid (MCPBA) yielded the corresponding sulfones 9 (Scheme 
2). The C-4 unsubstituted intermediate 10 was synthesised by reduction of 6b with NaBH4 in ethanol 
at 0 ºC. 31 Finally, reaction of intermediates 7-10, with benzyl isocyanate gave the desired 
compounds 5 in good yield. 
 
2. Enzyme Inhibition Studies 
The series of β-lactams, 5a-d, lacking substituents at the C-3 position was prepared to assess the 
impact of a leaving group at C-4 on porcine pancreatic elastase (PPE) inhibition when interaction 
with the S1 primary recognition site (Schechter and Berger, Biochem Biophys Res Comm, 25, 
157.162, 1967) of elastase is reduced. PPE is a readily available elastase that shares a conserved 
catalytic triad consisting of Ser195, His57 and Asp102 with HLE. 35 The primary specificity pocket 
of PPE is slightly less hydrophobic and smaller than that of HLE, showing preference of small-sized 
aliphatic side chains such as alanine. 35  The kinetic studies carried out at pH 7.2 and 25ºC, using the 
incubation method 32, showed that β-lactams 5b-d containing leaving groups are time-dependent 
inhibitors of PPE, while the C-4 unsubstituted counterpart 5a is inactive up to a concentration of 1 
mM. The second-order rate constants for PPE inactivation, kinact/ Ki, (Table 1) were determined from 
the plots of pseudo-first-order inhibition rate constant, kobs, versus [I] (Figure1). The sulfone 
derivative 5d proved to be a potent inhibitor of PPE, with a kinact/ Ki,  value of 290 M
-1s-1, thus 
suggesting that the sulfone group is a very powerful activator of the β-lactam carbonyl carbon atom 
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towards the Ser195 hydroxyl group even in the absence of an adequate molecular recognition moiety 
at C-3 in the β-lactam scaffold. 
Further evidence of the efficiency of 5d as irreversible inhibitor of PPE comes from the 
titration of enzyme activity. 33 The number of equivalents required to inactivate PPE was calculated 
by plotting the fraction of remaining enzyme activity, v/v0, after a 30 min incubation period versus 
the initial ratio of inhibitor to enzyme, i.e. [I]/[E]0. For levels of inhibition of up to 90% of the 
original enzyme activity, the extent of inactivation was found to depend linearly on the inhibitor to 
enzyme molar ratio (Figure 2), and extrapolation of the line to v/v0 = 0 shows that it required 
approximately 1.2 equiv of 5d to completely inactivate PPE. Interestingly, such high inhibitory 
efficiency is similar to that reported for HLE inactivation by 3,3-diethyl monobactams and 
cephalosporins.35(Green, ABB) 
In contrast to the C-3 unsubstituted series, their 3,3-diethyl counterparts 5e-j were completely 
inactive against PPE in concentrations up to 0.5 mM. However, β-lactams 5e-j inhibited HLE very 
efficiently in a time-dependent fashion. The pseudo-first-order rate-constants, kobs, for HLE 
inactivation were determined using the progress-curve method. 34 For compound 5f, a linear 
dependence of kobs on inhibitor concentration was observed (Figure 1B); and correction for the 
concentration and Michaelis constant of the substrate yielded the second-order rate constant for 
inhibition, (kinact/Ki), as the slope (Table 1). For compounds 5g and 5h, the individual kinetic 
parameters Ki and kinact were obtained by determining kobs as a function of the inhibitor concentration 
28 while for the remaining β-lactams (5e, 5i and 5j) the kinact/Ki values were determined by 
calculating kobs/[I] (Table 1). The second-order rate-constants for HLE inactivation, kinact/ Ki, are 
within the range of 105 to 106 M-1s-1, which reflects the stringent S1 subsite specificity of this enzyme 
toward hydrophobic substituents with three or four carbon atoms (e.g. leucine). 25,31,35,36 Finally, 
sulfones 5h and 5i present kinact/Ki values superior to that of the Merck Company’s compound 
M618614 used as standard in our assays. 
 
 
3. X-Ray Crystallography Studies 
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PPE was incubated with 5d  for 30 min, Good quality crystals were grown and subjected to x-
ray analysis.45 The electron density maps at the catalytic site indicate that PPE inactivation by 5d 
involves β-lactam ring-opening, as revealed by the ester formed with Ser195 Oγ (Figure 3). 
Moreover, inspection of the maps calculated at 1.66 Å resolution shows that acylation of PPE by 5d 
also involves the departure of sulfinate from C-4. Interestingly, the crystal structure reveals the 
presence of a hydroxyl group at C-3 (β-lactam numbering) (Scheme 3). This hydroxyl group 
establishes H-bonds to water molecules while the ester carbonyl group is H-bonded to the NH 
backbone of Gln192. Furthermore, the adjacent urea NH groups are within H-bonding distance to 
water molecules, as shown in Figure 3. This was a somewhat unexpected result when compared with 
those from previous X-ray crystallographic studies with other β-lactams containing leaving groups at 
C-4. For example, inactivation of PPE by 4-aryloxy-3,3-diethyl-β-lactams leads to a carbinolamine 
acyl-enzyme, resulting from reaction of water at C-4 of the imine intermediate.26 When a single 1-
hydroxyethyl substituent is present at C-3, an enamine acyl-enzyme is formed presumably from a 
retro-aldol reaction on the imine precursor. 26  
We wondered if this pattern of reactivity was inherent to 5d or a function of the enzyme 
active site. Therefore we undertook reaction of inhibitor 5d with sodium methoxide in methanol, 
which has been reported as a good model reaction for the acylation of serine enzymes. 37,38 The 
product of this reaction was 3-benzylpyrimidine-2,4(1H,3H)-dione, 11, in 80% yield (Scheme 4). 
This result is consistent with MeO--catalyzed β-lactam ring opening followed by pyrimidine ring 
formation and phenylsulfinate elimination (or first the elimination then the ring closure). Clearly, the 
enzyme active site must preclude the ring closure process; moreover, the acyl-enzyme equivalent to 
11 would be a cis-enamine and this would be expected to add water to C-4 (β-lactam numbering) 
rather than to the C-3 atom that is evident in Figure 3, thus suggesting that a different pathway may 
be available in the active site of PPE subsequently to β-lactam ring-opening. Although the nature of 
such pathway is currently unclear, it is unlikely to be the rate-limiting step in the enzyme inactivation 
process (see below). In this regard, it is of interest to note that the distance between C-4 (β-lactam 
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numbering) of PPE-5d complex and the Cα of Gln192 is only 3.4 Å; this close approach might 
suggest a reason as to why the presence of a hydroxyl group in the C-4 position is precluded. 
 
4. Alkaline Hydrolysis     
It has been suggested that the magnitude of the second-order rate-constant, kOH, for the alkaline 
hydrolysis of potential inhibitors of enzymes containing a catalytic serine is a crude indicator for 
their ability to be effective and therapeutically useful acylating agents. 37,39,40 Comparison of the kOH 
values presented in Table 1 reveals that the reactivity of β-lactams 5 correlates poorly to the pKa of 
the leaving group at C-4 of the β-lactam moiety. A poor correlation between log kOH values for the 
3,3-diethyl series 5e-j and the pKa of the leaving group at C-4 was observed, corresponding to a βlg 
value of -0.05, indicating that there is essentially no change in the effective charge on the leaving 
group on going from the ground state to the transition state. These results are comparable to those 
reported for the alkaline hydrolysis of the vinylogous cephalosporins containing a potential leaving 
group at C-3’ (4, n = 0), for which a βlg value close to zero was also determined.
41   
In contrast, log kOH- values correlate with σI values for the substituents at C-4, including 
those that are not expelled, yielding Hammett ρI values of 2.8 and 3.4 for the series 5a-d and 5e-j, 
respectively (Figure 4). These ρI values are consistent with rate-limiting attack of hydroxide on the 
β-lactam carbonyl atom and indicate that the effect exerted by C-4 substituents on the alkaline 
hydrolysis of 5 is purely inductive. 
The higher ρI value determined for the 3,3-diethyl series when compared to that of the C-3 
unsubstituted series is consistent with the formation of a high energy tetrahedral intermediate in 
which the two C-O bonds are eclipsed with the ethyl groups at C-3. According to the Hammond 
postulate, this implies a later transition state along the reaction coordinate with significant negative 
charge build-up, thereby being more susceptible to the electronic effects of the C-4 substituents. The 
ρI value determined here for the monobactams 5 is higher than the corresponding ρI value of 1.35 
reported for the alkaline hydrolysis of cephalosporins, 42 a difference that almost certainly reflects the 
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shorter distance between the electron-withdrawing substituents and the nitrogen atom in the β-lactam 
scaffold of 5.  
 
6. Structure-activity Relationships  
Insight into how a particular substituent promotes the ability of the enzyme to use its catalytic 
apparatus to increase the rate of acylation through β-lactam ring-opening can be obtained by the 
enzyme rate enhancement factor (EREF); this is the ratio of second-order rate-constant for enzyme 
inactivation to the second-order rate-constant for the alkaline hydrolysis, i.e. (kinact/Ki)/kOH or 
(kobs/[I])/kOH.
37,43 Remarkably, the 3,3-diethyl β-lactams 5e-j exhibit EREF values ca. 104 higher than 
those of their C-3 unsubstituted analogues 5b-d (Table 1). The differences in EREF between the two 
series of β-lactams largely reflect the importance of the alkyl substituents at C-3 in promoting an 
efficient molecular recognition by the S1 site of the enzyme. This interaction probably positions the 
β-lactam carbonyl within the oxyanion hole, facilitating successful nucleophilic attack by Ser-195, 
and thus enhancing the rate of β-lactam ring-opening. 31 Clearly, the favourable binding energy 
between the enzyme and the C-3 substituents overcomes the strain energy in the tetrahedral 
intermediate en route to the acyl-enzyme.   
As with alkaline hydrolysis, enzyme inactivation efficiency is not dependent on the pKa of the 
leaving group at C-4. However, a good correlation was found between the logarithm of the second-
order rate-constants of inactivation and the σI values for the substituents at C-4, including X = H 
(5e), which corresponds to a ρI value of 2.5 for compounds 5e-j (Figure 4). This ρI value is higher 
than that reported for HLE inactivation by cephalosporin sulfones (4, X = β-MeO, n = 2; ρI = 1.83 
20), again reflecting the shorter distance between the substituents and the nitrogen atom in the β-
lactam scaffold 5. Compared with the alkaline hydrolysis of 5 (ρI of 3.4), the HLE reaction seems to 
involve an earlier transition-state with less negative charge buildup. This effect can be ascribed, at 
least in part, to the favourable non-covalent interactions with the primary specificity pocket which 
allows the enzyme to stabilize the transition-state and to make full use of its catalytic machinery to 
increase the rate of acylation through β-lactam ring-opening. This is consistent with the EREF values 
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for 5e-j ranging from 105 to 106, which indicate that HLE is facilitating the expulsion of the urea 
anion from the tetrahedral intermediate when compared to the hydroxide-induced hydrolysis. 
 
In conclusion, the effectiveness of monobactams as elastase inhibitors is strongly dependent 
on the effect of C-3 substituents on the molecular recognition by the enzyme as well as on the effect 
of C-4 substituents on chemical reactivity that leads to serine acylation. The rate limiting step in 
elastase inactivation is the formation of the tetrahedral intermediate, and β-lactam ring-opening is not 
concerted with the departure of a leaving group from C-4. Monobactam sulfones emerged as very 
potent inhibitors of elastase due to the strong electron-withdrawing properties of the sulfone, 
although the departure of sulfinate from C-4 might be relevant to the chemistry of enzyme 
inactivation. 
  
 
EXPERIMENTAL 
 
General  
Melting points were determined using a Kofler camera Bock Monoscope M and are uncorrected. The 
infrared spectra were collected on a Nicolet Impact 400 FTIR infrared spectrophotometer and the 
NMR spectra on a Brucker 400 Ultra-Shield (400 MHz) in CDCl3; chemical shifts, δ, are expressed 
in ppm, coupling constants, J, are expressed in Hz. Low-resolution mass spectra were recorded using 
VG Mass Lab 20-250, VG Quattro or HP5988A mass spectrometers. Elemental analyses were 
performed by Medac Ltd., Brunel Science Centre, Englefield Gree Egham, TW20 0JZ, UK or by 
ITN, Chemistry Unit, Sacavém, Portugal. UV-vis assays were recorded either on a Shimadzu UV-
1603 or UV-2100 PC spectrophotometers. TLCs were performed on a Merck grade aluminium 
plates, silica gel 60 F254, and visualized by UV light and/or iodine. Preparative column 
chromatography was performed on silica gel 60 from Merck (70-230 mesh ASTM). DCM, TEA and 
benzene were purified and dried before use. Solvents and buffer materials for enzyme assays were of 
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analytical reagent grade and were purchased from Merck or Sigma. PPE, MeO-Suc-Ala-Ala-Pro-
Val-p-NA and N-Suc-Ala-Ala-Ala-pNA were purchased from Sigma and HLE was purchased from 
Calbiochem.  
 
General procedure for the synthesis of N-carbamoylazetidin-2-one derivatives 
Benzyl isocyanate (4.2 mmol) and subsequently triethylamine (4.2 mmol) were slowly added to a 
solution of the appropriate azetidin-2-one 7-10 (3.5 mmol) in dichloromethane (3 mL), The reaction 
was stirred at room temperature and monitored by TLC. After completion of the reaction, the 
solution was evaporated under reduced pressure. The product was purified by column 
chromatography. 
 
N-Benzylcarbamoylazetidin-2-one, 5a. Purified by column chromatography on silica gel 
(dichloromethane-ethyl acetate 9.5:0.5); 66%; m.p. 62-64 ºC, νmáx (film) 3335, 1764, 1685 cm
-1; δH 
3.08 (2H, t, J = 4.8); 3.68 (2H, t, J = 4.8); 4.50 (2H, d, J = 6.0); 6.89 (1H, brs); 7.28 - 7.38 (5H, m); 
δC 36.16, 37.28, 43.80, 127.70, 127.74, 128.80, 137.99, 150.09, 167.11; ESI-MS m/z 204 (MH
+); 
Anal. calcd. for C11H12N2O2: C, 64.69; H, 5.92; N, 13.72; found: C, 65.50; H, 6.10; N, 13.12. 
 
N-Benzylcarbamoyl-4-phenoxyazetidin-2-one, 5b. Purified by column chromatography on silica 
gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 85%; m.p. 129-130ºC; νmáx (film) 3368, 
1780, 1708 cm-1; δH 3.17 (1H, dd, J = 16.0, 1.2); 3.46 (1H, dd, J = 16.0, 4.4); 4.52 (2 H, dd, J = 14.4, 
5.6), 6.07 (1H, dd, J = 4.4, 1.2); 6.88 (1H, brs); 7.10 (1H, t, J = 7.2); 7.15 (2H, d, J = 8.0); 7.31–7.39 
(7H, m); δC 43.76, 45.51, 78.76, 117.14, 123.21, 127.00, 128.78, 129.72, 137.56, 156.14, 164.42; 
ESI-MS m/z 297.52 (MH+); Anal. calcd. for C17H16N2O3: C, 68.91, H, 5.44, N, 9.45; found, C, 69.12, 
H, 5.61, N, 9.19. 
 
N-Benzylcarbamoyl-4-phenylthioazetidin-2-one, 5c. Purified by column chromatography on silica 
gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 80%; m.p. 78-79 ºC, νmáx (film) 3366, 3036, 
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2908, 1773, 1698 cm-1; δH 2.88 (1H, dd, J = 16.4, 2.8); 3.40 (1H, dd, J = 16.4, 2.8); 4.47 (1H, dd, J = 
15.0, 6.0); 4.54 (1H, dd, J = 15.0, 6.0); 5.29 (1H, dd, J = 5.4, 2.8), 6.81 (1H, brs); 7.30 -7.56 (10H, 
m); δC 43.41, 44.13; 56.56; 127.73, 127.85, 129.08, 129.47, 129.69, 130.42, 135.33, 139.69, 166.02, 
189.23, ESI-MS m/z 334.84 (MNa+); Anal. calcd. for C17H16N2O2S: C, 65.36; H, 5.16; N, 8.97; 
found C 64.85; H 5.08; N 8.89. 
 
N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one, 5d. Purified by column chromatography on 
silica gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 81%; m.p. 159-161 ºC, νmáx (film) 
3374, 3064, 3031, 2978, 1789, 1711 cm-1; δH 3.48 (1H, dd, J = 16.8, 6.0); 3.67 (1H, dd, J = 16.8, 
2.8); 4.33 (1H, dd, J = 14.8, 6.0); 4.39 (1H, dd, J = 14.8, 6.0); 5.20 (1H, dd, J = 6.0, 2.8), 6.65 (1H, 
brs); 7.23 (2H, dd, J = 8.0, 1.2); 7.31 -7.38 (3H, m); 7.58 (2H, t, J = 8.0); 7.74 (1H, dt, J = 8.0, 1.2); 
7.96 (2H, dd, J = 8.0, 0.8); δC 39.43, 43.86, 65.84, 127.58, 127.79, 128.77, 129.28, 129.39, 134.88, 
136.75, 137.28, 148.39, 164.27; EI-MS m/z: 344.00 (M+); Anal. calcd. for C17H16N2O4S: C, 59.29; 
H, 4.68; N, 8.13; found C, 59.55; H, 5.25; N, 7.97. 
 
N-Benzylcarbamoyl-3,3-diethylazetidin-2-one, 5e. Purified by column chromatography on silica 
gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 83% as a colourless oil, νmáx (film) 3364, 
3071, 3031, 2969, 2924, 2875, 1757, 1702 cm-1; δH 1.00 (6H, t, J = 7.6); (4H, q, J = 7.6); 3.42 (2H, 
s); 4.50 (2H, d, J = 6.0); 6.93 (1H, brs); 7.28 – 7.38 (5H, m); δC 8.70, 25.71, 43.75, 47.04, 59.31, 
127.44, 127.54, 127.65, 128.65,128.71, 137.98, 150.95, 172.83; ESI-MS m/z 261.10 (MH+); Anal. 
calcd. for C15H20N2O2: C, 69.20, 7.74, N, 10.76; found C, 68.80; 7.80; 10.59. 
 
N-Benzylcarbamoyl-3,3-diethyl-4-phenoxyazetidin-2-one, 5f. Purified by column chromatography 
on silica gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 81%; m.p. 58-59 ºC; νmáx (film) 
3366, 3064, 3031, 2970, 2939, 2880, 1770, 1710 cm-1; δH 1.00 (3H, t, J = 7.6 Hz ); 1.06 (3H, t, J = 
7.6); 1.77-1.84 (3H, m); 1.99 (1 H, dq, J = 14.4, 7.2); 4.47 (1H, dd, J = 15.6, 6.0); 4.51 (1H, dd, J = 
15.6, 6.0); 5.68 (1H, s); 6.93 (1H, brs); 7.07 (1H, t, J = 7.2); 7.22-7.35 (9H, m); δC 8.58, 8.84, 21.23, 
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23.86, 43.75, 64.35, 86.76, 117.76, 123.17, 127.63, 127.67, 128.76, 129.67, 137.66, 150.14, 157.47, 
172.23; ESI-MS m/z  353.29 (MH+); Anal. calcd. for C21H24N2O3: C, 71.57, H, 6.86, N, 7.95; found 
71.84, 6.78, 8.18. 
 
N-Benzylcarbamoyl-3,3-diethyl-4-phenylthioazetidin-2-one, 5g. Purified by column 
chromatography on silica gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 70%; m.p. 80-81 
ºC; νmáx (film) 3361, 3061, 2968, 1758, 1701 cm
-1; δH 0.94 (3H, t, J = 8.0 Hz ); 1.06 (3H, t, J = 8.0); 
1.75-1.98 (4H, m); 1.99 (1 H, dq, J = 14.4, 7.2); 4.51 (1H, dd, J = 15.6, 6.0); 4.55 (1H, dd, J = 15.6, 
6.0); 5.06 (1H, s); 6.95 (1H, brs); 7.28-7.39 (8H, m); 7.77 (2H, d, J = 8.0); δC 8.43, 9.01, 23.11, 
24.74, 43.74, 63.95, 71.42, 127.60, 127.65, 128.17, 128.74, 129.19, 133.24, 137.71, 150.13, 172.04; 
EI-MS m/z 368.15 (M+); Anal. calcd. for C21H24N2O2S: C, 68.45, H, 6.56, N, 7.60; found, C, 68.22, 
H, 6.93, N, 8.03.  
 
N-Benzylcarbamoyl-3,3-diethyl-4-phenylsulfonylazetidin-2-one, 5h. Purified by column 
chromatography on silica gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 63%; m.p. 142-
144 ºC; νmáx (film) 3366, 3060, 3041, 2971, 1778, 1711 cm
-1; δH 1.01 (3H, t, J = 7.2 Hz ); 1.06 (3H, 
t, J = 7.2); 1.68 (1 H, dq, J = 14.4, 7.2); 1.95 (1 H, dq, J = 14.4, 7.2); 2.20 (1 H, dq, J = 14.4, 7.2); 
2.47 (1 H, dq, J = 14.4, 7.2); 4.21 (1H, dd, J = 14.8, 6.0); 4.33 (1H, dd, J = 14.8, 6.0); 4.75 (1H, s); 
6.66 (1H, brs); 7.14 (2H, d, J = 7.6); 7.19-7.28 (3H, m); 7.47 (2H, t, J = 7.6); 7.61 (1H, t, J = 7.6); 
7.85 (2H, t, J = 7.6); δC 8.56, 8.90, 20.86, 25.12, 43.85, 67.05, 74.72, 127.43, 127.69, 128.74, 
128.88, 129.18, 134.39, 137.36, 139.84, 148.99, 171.49; EI-MS m/z (M+) 400.05; Anal. calcd. for 
C21H24N2O4S: C, 62.98, H, 6.04, N, 6.99; found, C, 61.57, H, 6.86, N, 7.20.  
 
N-Benzylcarbamoyl-3,3-diethyl-4-benzylthioazetidin-2-one, 5i. Purified  by column 
chromatography on silica gel (elution with dichloromethane-ethyl acetate 9.5:0.5); 53% as an yellow 
oil, νmáx (film) 3365, 1759, 1701 cm
-1; δH 0.56 (3H, t, J = 7.4); 0.85 (3H, t, J = 7.4); 1.44-1.69 (4H, 
m); 3.99 (1H, d, J = 12.8); 4.06 (1H, d, J = 12.8); 4.31 (1H, dd, J = 15.3, 6.1); 4.36 (1H, dd, J = 15.3, 
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6.3); 4.70 (1H, s); 6.91 (1H, s); 7.10-7.27 (10H, m); δC 7.67; 8.90; 22.41; 24.44; 37.37; 43.61; 62.99; 
65.84; 127.63; 127.72; 127.81; 129.01; 129.07; 129.80; 138.79; 139.62;150.96; 172.35; HPLC-
ESIMS m/z (MH+) 382.02; Anal. calcd. for C22H26N2O2S; C, 69.10; H, 6.97; N, 7.30; found C, 
69.10, H, 6.90; N, 7.30. 
  
N-Benzylcarbamoyl-3,3-diethyl-4-benzylsulfonylazetidin-2-one, 5j. Purified by column 
chromatography on silica gel (elution with diethyl ether–light petroleum 1:1; 52%; m.p. 93-94 ºC; 
νmáx (film) 3365, 1778, 1313, 1165 cm
-1; δH 0.79 (3H, t, J = 7.4); 1.01 (3H, t, J = 7.5); 1.62 (1 H, dq, 
J = 14.5, 7.3); 1.84 (1H, dd, J = 14.5, 7.3); 2.08 (1H, dq, J = 14.5, 7.4); 2.52 (1H, dq, J = 14.6, 7.4); 
4.48 (1H, d, J = 13.9); 4.53 (2H, d, J = 5.9); 4.62 (1H, s); 5.01 (1H, d, J = 13.9); 6.95 (1H, t, J = 5.9); 
7.19-7.59 (10H, m); δC 8.27, 8.87, 20.90, 24.48, 44.12, 62.27, 66.46, 69.06, 127.59, 127.89, 128.91, 
129.07, 131.37, 137.08, 150.20, 171.22; EI-MS m/z 413.8 (MH+); Anal. calcd. for C22H26N2O4S; C, 
63.75; H, 6.32; N, 6.76; found C, 63.70, H, 6.40; N, 6.60. 
 
Large scale reaction of N-benzylcarbamoyl-4-phenylsulfonylazetidin-2-one with excess sodium 
methoxide 
N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one (0.29 mmol), 5h, was added to a solution of 
sodium methoxide (1.5 mmol) in methanol (15 mL). The reaction mixture was stirred at room 
temperature and monitored by TLC. The solvent was removed under reduced pressure and the 
residue was taken up in water (20 mL), acidified with HCl 10% until pH 2 and extracted with ethyl 
acetate (3x 30 mL). After drying and evaporating off the solvent, the residue was purified by column 
chromatography on silica gel (elution with dichloromethane-ethyl acetate 8:2), to yield the product 3-
benzylpyrimidine-2,4(1H,3H)-dione, 11, as a white solid (79%); m.p. 177-179 ºC (Lit 44, 181-182) ; 
νmáx (film) 3084, 2965, 1625, 1601 cm
-1; δH 5.12 (2H, s); 5.81 (1H, dd, J = 7.2, 1.2); 7.14 (1H, dd, J 
= 7.2, 6.0); 7.26-7.34 (3H, m); 7.46 (2H, d, J = 7.2); 9.35 (1H, brs); δC 43.71, 102.26, 127.70, 
128.46,128.80, 136.49, 138.17, 163.12; EI-MS m/z 202.05 (M+); Anal. calcd. for C11H10N2O2, C, 
65.34; H, 4.98; N, 13.85; found, C, 65.65, H, 5.25, N, 13.41. 
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Chemical kinetics 
All kinetic measurements were carried out at 25.0 ± 0.1 ºC and with an ionic strength adjusted to 0.5 
M by addition of NaClO4. Due to substrate solubility problems all buffers contained 20% (v/v) 
acetonitrile. Rate constants were determined using UV spectrophotometry by recording the decrease 
of substrate absorbance at fixed wavelength, using a spectrophotometer equipped with a temperature 
controller. In a typical run, reaction was initiated by adding a 15 µL aliquot of a 10-2 M stock 
solution of substrate in acetonitrile to a cuvette containing 3 mL of the buffer solution. The pseudo-
first-order rate constants, kobs, were obtained by least-squares treatment of log(At-A∞) data, where At 
and A∞ represent the absorbance at time t and at time infinity, respectively. Rate constants derived 
using this method were reproducible to ± 5%.  
 
Enzyme inactivation by the progress curve method  
Inactivation of HLE was assayed at 25 ºC by mixing 10 µL of HLE stock solution (2 µM in 0.05 M 
acetate buffer, pH 5.5) to a solution containing 10 µL of inhibitor in DMSO (200 µM), 20 µL of 
substrate MeO-Suc-Ala-Ala-Pro-Val-p-NA (50 mM in DMSO) and 960 µL of 0.1 M HEPES buffer, 
pH 7.2, and the absorbance was continuously monitored at 410 nm for 20 minutes. Control assays, in 
which the inhibitor was omitted, ran linearly. The pseudo-first order rate constants, kobs, for the 
inhibition of HLE were determined according to the slow-tight binding inhibition model 34 and 
involved the fitting of product concentration as a function of time to Eq. 1 by non-linear regression 
analysis using the routine ENZFIT (developed at the Faculty of Pharmacy, Lisbon), 
 
( )( ) 0/1 AkevvtvA obstksis obs +−−+= −       (1) 
 
where A is the absorbance at 410 nm, A0 is the absorbance at t = 0, vi is the initial rate of change of 
absorbance, vs is the steady-state rate and kobs is the first-order rate constant for the approach to the 
steady-state. The individual kinetic parameters Ki and kinact were obtained by determining kobs (in 
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duplicate or triplicate) as a function of the inhibitor concentration and by fitting the experimental 
data to Eq. 2 25. When a linear dependence of kobs on inhibitor concentration was observed (e.g. for 
5f), correction for substrate concentration and Michaelis constant yielded the second-order rate 
constant for inhibition, (kinact/Ki), as the slope and the first-order rate for the dissociation of the E⋅I 
complex, koff, as the intercept (Eq. 3) (see Fig. 1B). For the remaining β-lactams the kinact/Ki values 
were determined in duplicate or triplicate by calculating kobs/[I] and then correcting for the substrate 
concentration and Michaelis constant using Eq 4. 
 
[ ] [ ] [ ]( )IKSKIkk miinactobs ++= )/1(/        (2) 
 
( )[ ] [ ] )/1/(/ miinactoffobs KSIKkkk ++=       (3) 
 
[ ] ( ) [ ] )/1/(// miinactobs KSKkIk +=        (4) 
 
Enzyme inactivation by the incubation method  
Inhibition of PPE was assayed by Kitz and Wilson’s incubation method. 32 In a typical experiment, 
50 µL of inhibitor solution in DMSO were incubated at 25 ºC with 750 µL of 0.1 M HEPES buffer, 
pH 7.2, and 200 µL of PPE solution (50 µM in 0.1 M HEPES buffer, pH 7.2). Aliquots (100 µL) 
were withdrawn at different time intervals and transferred to a cuvette thermostated at 25 ºC, 
containing 895 µL of 0.1 M HEPES buffer, pH 7.2, and 5 µL of N-Suc-Ala-Ala-Ala-pNA (12.5 mM 
in DMSO). The absorbance was monitored at 390 nm for 60 seconds and the gradients of the slopes 
obtained of initial rate used as a measure of enzyme activity. The values of kobs for compounds 5b-d 
were determined in duplicates or triplicates from plots of ln(v/v0) versus incubation time, where v is 
the initial rate at time t and v0 is the initial rate of the control incubation without inhibitor. The plots 
of kobs versus [I] were linear and the potency of the inhibitors was determined in terms of the 
bimolecular rate constant kinact/Ki = kobs/[I]. 
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Partition ratio 
PPE solutions were incubated at 25 ºC with different concentrations of 5d solutions in 0.1 M HEPES 
buffer, pH 7.2, in a final volume of 1 mL. After 30 minutes incubation, a 100 µL aliquot of the 
reaction mixture was withdrawn and assayed for remaining enzyme activity as described previously.   
 
X-Ray Crystallographic Studies 
Porcine pancreatic elastase (PPE) was incubated with inhibitor 5d for 30 min. Good quality crystals 
were grown in 200 mM sodium sulfate and 100 mM sodium acetate at pH 5.1 (293 K) using the 
sitting drop vapour-diffusion method45. X-ray diffraction data were collected to 1.66 Å at 
synchrotron beamline X11 at DESY (Hamburg, Germany), using a wavelength of 0.82 Å. The 5d-
PPE complex has been refined to give an R-factor of 15.6% and R-free of 18.6%. The structure is 
generally well defined within the electron density maps, showing an average B factor of 10.5 Å2 for 
all protein atoms. The final model comprises 240 amino acid residues, 316 water molecules, the 
inhibitor 5d without the C-4 PhSO2
- leaving group, two glycerol molecules, one sulfate ion and one 
sodium ion, which is hexa-coordinated to side-chain atoms of Glu80, Asp77, Gln75, Asn72, Glu70 
and a water molecule. Alternated conformations were modelled for the side chains of Gln23, Gln75, 
Val83 and Ser189, with 50% occupancy each. All protein residues lie within allowed regions of the 
Ramachandran plot and the relevant refinement statistics is presented in Table 2. The overall protein 
structure of the 5d-PPE complex is very similar to that of the native enzyme (PDB code 1QNJ) and 
superposition of the Cα atoms shows a r.m.s. deviation of 0.089 Å. The numbering of 5d-PPE 
complex follows the common practice of using the bovine chymotrypsinogen A numbering. 46 
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Table 2. Data collection and crystallographic refinement statistics for the porcine pancreatic 
structure bound to 5d. 
Resolution range (Å) 37.95-1.66 
Refined model   
       R-factor (%) 15.6 
       R-free (%) 18.6 
       Nº of non H protein atoms  1833 
       Nº of solvent molecules 320 
Average B-factor (Å2)  
       Protein only 10.5 
       Inhibitor only 24.4 
       Solvent molecules 25.9 
Ramachandran plot 87.4 
       Residues in most most favoured regions of (%)  
       Residues in additional allowed regions (%) 12.6 
r.m.s. deviations   
       bond angles (º) 0.01 
       angle lengths (Å) 1.22 
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Figure 1. Dependence of kobs for enzyme inhibition on inhibitor concentration: (A), 5d, porcine 
pancreatic elastase; (B), 5f, human leuocyte elastase. 
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Figure 2. Inactivation of porcine pancreatic elastase as a function of the molar ratio of inhibitor 5d to 
enzyme. PPE (10 µM) and various amounts of inhibitor 5d (20-0.4 µM) in 0.1 M HEPES buffer, pH 
7.25, were incubated at 25 °C for 30 min, and aliquots were withdrawn for assay. 
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Figure 3. A stereoview of the CFF −0  electron density map calculated with Ser-195 and inhibitor 
5d (code JM48) omitted from the model. The omit map is contoured at 3σ and shows the acyl-
enzyme covalently linked to Ser195 with the corresponding interactions with PPE active site. 
 
 
 
 
 
 
 
 
 
 
 27
Figure 4. Plots of second-order rate-constants for the alkaline hydrolysis of C-3 unsubstituted β-
lactams 5a-d () and 3,3-diethyl-β-lactams 5e-j () and of second-order rate-constants for HLE 
inactivation by 3,3-diethyl-β-lactams 5e-j () against σI values for the X substituents in C-4. 
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Scheme 2 
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Scheme 4 
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Covalent enzyme-inhibitor complex (see Fig. 3) 
